<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335867</url>
  </required_header>
  <id_info>
    <org_study_id>812864</org_study_id>
    <secondary_id>P50DA012756</secondary_id>
    <nct_id>NCT01335867</nct_id>
  </id_info>
  <brief_title>Vigabatrin for Cocaine and Alcohol Dependence</brief_title>
  <acronym>VGB</acronym>
  <official_title>A Phase II, Double-Blind, Placebo-Controlled, Pilot Trial of Vigabatrin for the Treatment of Cocaine and Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of vigabatrin at reducing drug and
      alcohol use in individuals addicted to cocaine and alcohol. Vigabatrin is approved for the
      treatment of seizures. It has not been proven to be effective for the treatment of alcohol or
      cocaine dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypotheses in the proposed study will be tested with a 2-group design to assess the
      efficacy of vigabatrin compared to placebo. We will follow NIAAA's COMBINE Medical Management
      (MM) manual in weekly dispensing medications, safety checks and medication adherence. The
      psychosocial treatment will be Cognitive Behavioral Coping Skills Therapy (CBT). Subjects
      will be 60 men and women with current DSM-IV diagnoses of both cocaine and alcohol dependence
      who will be randomized to vigabatrin or placebo (30 subjects per group). All subjects will
      receive weekly sessions of CBT. The study length for each subject is comprised of a1-3 weeks
      of screening and baseline evaluations, an 8-week double-blind, placebo-controlled trial with
      CBT (medication phase), and one follow-up visit 12 weeks after starting study medication.

      Study medication will be initiated in Week 2. The research physician will explain the dosing
      regimen and subjects will be randomly assigned to receive either vigabatrin or identical
      placebo tablets. Subjects will receive 1 gram of vigabatrin or identical placebo tablets on
      medication days 1-3 then 1.5 grams or identical placebo tablets on days 4-7. The dose ids
      increased to 2 grams in week 2, 3 grams in weeks 4-7 and then reduced to 2 grams days 50-53,
      and to 1 gram on days 54-56
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    interim analysis of efficacy completed and termination recommended
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Reduction in Cocaine Use</measure>
    <time_frame>last 3 weeks of the trial</time_frame>
    <description>The primary outcome measure for reduction in cocaine use will be the number of benzoylecgonine (BE) negative urine samples. The main outcome is the number of participants in each group who reported all BE negative urine samples in the last three weeks of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Heavy Drinking Days</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary outcome measure for reduction in alcohol use will be recorded using the Timeline Followback method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of Cocaine Craving</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measures of cocaine craving at the end of the trial will be measured using the Brief Substance Craving Ccale. Craving intensity + Craving frequency + Craving Duration each measured on a 4 point scale. Sum of the three scales was overall craving composite. Higher numbers meaning greater craving. Maximum score 12 minimum 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity and Improvement</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of subjects in each group rated as improved or very much improved at the end of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine Withdrawal Severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measure of cocaine withdrawal severity will include Cocaine Selective Severity Assessment scores. Minimum score is 0 Maximum score is 119 Higher score is indicative of worse cocaine withdrawal symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Alcoholism</condition>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Vigabatrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vigabatrin titrated to 3 grams daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo daily for three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin</intervention_name>
    <description>Vigabatrin escalated to 3 grams daily for 8 weeks</description>
    <arm_group_label>Vigabatrin</arm_group_label>
    <other_name>Sabril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo vigabatrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and females, 18 years of age or older.

          2. Meets DSM-IV criteria for current diagnoses of cocaine and alcohol dependence,
             determined by the SCID-IV.

          3. Used cocaine in the past 30 days and used no less than $200 of cocaine in a
             consecutive 30 day period over the 90 day period prior to intake. Meets the following
             drinking criteria as measured by the Timeline Followback (TLFB) (Sobell 1995) a drank
             within 30 days of intake day, b. reports a minimum of 48 standard alcoholic (avg. 12
             drinks/wk) in a consecutive 30-day period over the 90-day period prior to starting
             intake (i.e., a minimum of 40% days drinking), and c. has 2 or more days of heavy
             drinking (defined as greater than 4 drinks per day in males and greater than 3 drinks
             per day in females) in this same pre-treatment period.

          4. Three consecutive days of abstinence from alcohol directly prior to the day of
             randomization, determined by self-reports and confirmed by negative breathalyzer
             tests, and a Clinical Institute Withdrawal Scale for Alcohol (CIWA-AR) (Sullivan and
             Sellers 1989) score below eight. Subjects will be given 2 additional weeks beyond the
             screening week to attain the appropriate period of alcohol abstinence prior to
             randomization.

          5. Have a verifiable address of principal residence, lives a commutable distance from the
             TRC and agrees to attend all research visits including follow-up visits.

          6. Speaks, understands, and prints in English

          7. Ability to give informed consent

        Exclusion Criteria:

          1. Meets DSM IV criteria for dependence on any substance other than cocaine and alcohol
             (except nicotine and cannabis), determined by the SCID. Needs treatment with any
             psychoactive medications including any anti-seizure medications (with the exception of
             diphenhydramine used sparingly, if necessary, for sleep).

          2. Meets current or lifetime DSM-IV criteria for schizophrenia or any psychotic disorder
             or organic mental disorder. Subject meets current DSM-IV diagnosis of any other
             clinically significant psychiatric disorder that will interfere with study
             participation as determined by the principal investigator.

          3. Has evidence of a history of significant hematological, pulmonary, endocrine,
             cardiovascular, renal or gastrointestinal disease.

          4. Severe physical or medical illnesses such as AIDS, active hepatitis, significant
             hepatocellular injury as evidenced by elevated total bilirubin levels (&gt;1.3 mg/dl), or
             elevated levels (over 4.5x normal) of aspartate aminotransferase (AST), and/or alanine
             aminotransferase (ALT). Patients with Gilberts Syndrome will not be excluded.

          5. Use of an investigational medication in the 30 days prior to randomization.

          6. History of prior treatment with vigabatrin

          7. History of prior treatment with drugs with known retinotoxicity

          8. History of visual field defects or predisposing factors, including glaucoma, severe
             myopia, retinal disorders, cataracts, diabetes, or uncontrolled hypertension.

          9. Is female and tests positive on a pregnancy test, is contemplating pregnancy in the
             next 6 months, is nursing, or is not using an effective contraceptive method (if
             relevant). Acceptable methods of contraception include barrier methods (diaphragm or
             condom with spermicide, female condom), intrauterine progesterone contraceptive
             system, levonorgrestrel implant, and medroxyprogesterone acetate contraceptive
             injection, copper IUD, vaginal contraceptive film, cervical cap, contraceptive foam,
             hormonal vaginal contraceptive ring (NuvaRing®) or oral contraceptives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle M Kampman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania, Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/csa/</url>
    <description>University of Pennsylvania Center for Studies of Addictions</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <results_first_submitted>June 1, 2015</results_first_submitted>
  <results_first_submitted_qc>June 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 12, 2015</results_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vigabatrin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vigabatrin</title>
          <description>Vigabatrin: Vigabatrin escalated to 3 grams daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vigabatrin</title>
          <description>Vigabatrin: Vigabatrin escalated to 3 grams daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo pills</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="7.97"/>
                    <measurement group_id="B2" value="48" spread="6.81"/>
                    <measurement group_id="B3" value="47" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Reduction in Cocaine Use</title>
        <description>The primary outcome measure for reduction in cocaine use will be the number of benzoylecgonine (BE) negative urine samples. The main outcome is the number of participants in each group who reported all BE negative urine samples in the last three weeks of the trial.</description>
        <time_frame>last 3 weeks of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vigabatrin</title>
            <description>Vigabatrin: Vigabatrin escalated to 3 grams daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Reduction in Cocaine Use</title>
          <description>The primary outcome measure for reduction in cocaine use will be the number of benzoylecgonine (BE) negative urine samples. The main outcome is the number of participants in each group who reported all BE negative urine samples in the last three weeks of the trial.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.14</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Heavy Drinking Days</title>
        <description>The primary outcome measure for reduction in alcohol use will be recorded using the Timeline Followback method.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vigabatrin</title>
            <description>Vigabatrin: Vigabatrin escalated to 3 grams daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Heavy Drinking Days</title>
          <description>The primary outcome measure for reduction in alcohol use will be recorded using the Timeline Followback method.</description>
          <units>proportion of heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".26" spread=".18"/>
                    <measurement group_id="O2" value=".20" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Cocaine Craving</title>
        <description>Measures of cocaine craving at the end of the trial will be measured using the Brief Substance Craving Ccale. Craving intensity + Craving frequency + Craving Duration each measured on a 4 point scale. Sum of the three scales was overall craving composite. Higher numbers meaning greater craving. Maximum score 12 minimum 0.</description>
        <time_frame>8 weeks</time_frame>
        <population>subjects receiving vigabatrin or placebo who were available at the end of the trial to provide data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vigabatrin</title>
            <description>vigabatrin 3 grams daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Cocaine Craving</title>
          <description>Measures of cocaine craving at the end of the trial will be measured using the Brief Substance Craving Ccale. Craving intensity + Craving frequency + Craving Duration each measured on a 4 point scale. Sum of the three scales was overall craving composite. Higher numbers meaning greater craving. Maximum score 12 minimum 0.</description>
          <population>subjects receiving vigabatrin or placebo who were available at the end of the trial to provide data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="2.3"/>
                    <measurement group_id="O2" value="0.38" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.24</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Severity and Improvement</title>
        <description>Number of subjects in each group rated as improved or very much improved at the end of the trial</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vigabatrin</title>
            <description>Vigabatrin titrated to 3 grams daily for 12 weeks
Vigabatrin: Vigabatrin escalated to 3 grams daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo daily for 12 weeks
Placebo: Placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Severity and Improvement</title>
          <description>Number of subjects in each group rated as improved or very much improved at the end of the trial</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.20</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Withdrawal Severity</title>
        <description>Measure of cocaine withdrawal severity will include Cocaine Selective Severity Assessment scores. Minimum score is 0 Maximum score is 119 Higher score is indicative of worse cocaine withdrawal symptoms.</description>
        <time_frame>8 weeks</time_frame>
        <population>subjects receiving vigabatrin or placebo who were available at the end of the trial to provide data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vigabatrin</title>
            <description>Vigabatrin titrated to 3 grams daily for 8 weeks
Vigabatrin: Vigabatrin escalated to 3 grams daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo daily for three weeks
Placebo: Placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Withdrawal Severity</title>
          <description>Measure of cocaine withdrawal severity will include Cocaine Selective Severity Assessment scores. Minimum score is 0 Maximum score is 119 Higher score is indicative of worse cocaine withdrawal symptoms.</description>
          <population>subjects receiving vigabatrin or placebo who were available at the end of the trial to provide data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="8.1"/>
                    <measurement group_id="O2" value="6.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.64</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vigabatrin</title>
          <description>Vigabatrin: Vigabatrin escalated to 3 grams daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo pills</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sore Knees</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kyle M. Kampman, M.D.</name_or_title>
      <organization>University of Pennsylvania Treatment Research Center</organization>
      <phone>215 746 2764</phone>
      <email>kampman@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

